Updated on 3 August 2026
Point-of-care Early Cancer Breath Testing
Founder & CEO at Qi Diagnostics Limited
China (Hong Kong)
About
We are proud to be the first team to develop a cancer-specific breath marker and a POC breathalyzer device with high sensitivity and promising clinical applicability in detecting cancer tumors.
Our clinical studies have demonstrated the detection of early stage 0–I microinvasive lung adenocarcinoma that screens out higher risk patients for prioritized follow up and better utilize the limited medical resources in the hospital. Also, real-time cancer treatment response monitoring that can flag progression ahead of imaging addition to how doctors monitor patients in routine practice.
Project Location
- China (Hong Kong)
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Health Technology
- Medical Technology
Investment Capital Required
- 2,500,001 to 5,000,000 USD
Interested Format of Cooperation
- Convertible Loan
- Direct Equity Investment
- Minority Shareholdings
- Open for Negotiation
Preferred Financing Model
- Debt
- Equity
- Public / Alternative Financing
- Open for negotiation
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
Financial Services
- Institutional Investment
- Private Equity & Venture Capital
Organisation
China (Hong Kong)
Similar opportunities
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Financial Services
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Investment / Financing Discussion
- M&A / Strategic Acquisition Opportunity
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China
Project
Cannabis and Drug Breath Testing
- No
- Yes
- Debt
- Equity
- Technology
- Joint Venture
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Professional Services
- 500,001 to 1,000,000 USD
- Direct Equity Investment
- Institutional Investment
- Feasibility Study Completed
- Public / Alternative Financing
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
- Public–private partnership / Concession
Grover Cheung
Founder & CEO at Qi Diagnostics Limited
China (Hong Kong)
Project
AI-Enabled Quantitative MRI Platform for Early Disease Assessment
- No
- No
- Equity
- Technology
- Private Project
- Convertible Loan
- Equity (private)
- Financial Services
- Open for Negotiation
- Direct Equity Investment
- 1,000,001 to 2,500,000 USD
- 7,500,001 to 10,000,000 USD
- Investment / Financing Discussion
Carmen Ng
CEO at CAPRiser Group
Canada